Catabasis Pharmaceuticals to Present at 2020 Muscular Dystrophy Association Virtual Poster Session
During the Virtual Poster Session, Catabasis and collaborators will present three posters entitled:
Baseline Characteristics of Patients Enrolled in PolarisDMD, a Phase 3 Trial of Edasalonexent for Duchenne Muscular Dystrophy.
Richard S. Finkel; Craig McDonald; H. Lee Sweeney; Kathryn Wagner; Erin Neil; Maria Mancini; James MacDougall; Joanne M. Donovan.
Edasalonexent Treatment in Young Boys with Duchenne Muscular Dystrophy is Associated with Age-Normative Growth and Normal Adrenal Function.
Erika L. Finanger; Richard S. Finkel; Gihan I. Tennekoon; Krista Vandenborne; H. Lee Sweeney; Perry Shieh; Sabrina W. Yum; Maria Mancini; James MacDougall; Joanne M. Donovan.
Experience with Edasalonexent Demonstrates Ability of 4 to 7 Year Old Boys with Duchenne Muscular Dystrophy to Take Soft-gel Capsules in Trials.
Maria Mancini; Gigi Shafai; Joanne M. Donovan; Sachin Chandran; Richard S. Finkel.
The poster session will be available to registered conference attendees and will be made available under “Our Science” on the company website at www.catabasis.com.
About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is an investigational oral small molecule designed to inhibit NF-kB that is being developed as a potential foundational therapy for all patients affected by DMD, regardless of their underlying mutation. In DMD the loss of dystrophin leads to chronic activation of NF-kB, which is a key driver of skeletal and cardiac muscle disease progression. Our ongoing global Phase 3 PolarisDMD trial is evaluating the efficacy and safety of edasalonexent for registration purposes. Edasalonexent is also being dosed in the GalaxyDMD open-label extension trial. In our MoveDMD Phase 2 trial and open-label extension, we observed that edasalonexent preserved muscle function and substantially slowed disease progression compared to rates of change in a control period, and significantly improved biomarkers of muscle health and inflammation. The FDA has granted orphan drug, fast track, and rare pediatric disease designations and the
Investor and Media Contact
T: (617) 349-1971